title: Prolonged treatment with ursodeoxycholic acid for primary biliary cirrhosis.
abstract: Eighteen patients affected with biopsy-proved primary biliary cirrhosis (PBC) (histological stage III and IV) received ursodeoxicholic acid (UDCA) 600 mg for 1 year. Signs and symptoms and biochemical tests (glutamic and oxalcetic transaminase, glutamic and pyruvic transaminase, bilirubine, gamma-glutamyl transpeptidase, alkaline phosphatase, leucine aminopeptidase, bile acids, plasma proteins electrophoresis, immunoglubulins A, G and M) and antimitochondrial antibodies were evaluated before the treatment and every four months during the treatment. The results were compared with those obtained in 8 untreated patients affected PBC. The control group of patients were comparable (as far as age, histological stage, biochemical tests are concerned) to the group who received UDCA. Bilirubine, ALP, gamma-GT and LAP decreased during the treatment with UDCA and remained lower than baseline values until the end of the observation (12 months), while no changes occurred in the untreated patients. Both in the treated and untreated group plasma protein electrophoresis, serum immunoglubulins A, G and M remained unchanged, as well as anti-mitochondrial antibody. A moderate reduction of transaminases and bile acids was observed in the group of patients receiving UDCA but it did not reach statistical significance. In 16 out of the 18 treated patients pruritus disappeared and resulted diminished in the remaining 2 patients. No significant amelioration of pruritus was observed in the patients who did not receive UDCA. In conclusion, our data show that prolonged treatment with UDCA drastically reduces pruritus and improves cholestasis biochemical tests in patients affected with symptomatic PBC.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Internal Medicine, Hospital, Piacenza.
authors.forename: G
authors.initials: G
authors.lastname: Crippa
authors.forename: C
authors.initials: C
authors.lastname: Cagnoni
authors.forename: A
authors.initials: A
authors.lastname: Castelli
authors.forename: C
authors.initials: C
authors.lastname: Concesi
authors.forename: S
authors.initials: S
authors.lastname: Girometta
authors.forename: D
authors.initials: D
authors.lastname: Pancotti
authors.forename: E
authors.initials: E
authors.lastname: Sverzellati
authors.forename: G
authors.initials: G
authors.lastname: Tacchini
authors.forename: M G
authors.initials: MG
authors.lastname: Pierfranceschi
authors.forename: G C
authors.initials: GC
authors.lastname: Carrara
mesh_terms: D000328:Adult; D002779:Cholestasis / Q000188:drug therapy / Q000209:etiology; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D011537:Pruritus / Q000188:drug therapy / Q000209:etiology; D016896:Treatment Outcome; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*
chemical_list: D014580:Ursodeoxycholic Acid